Actinium-225 PSMA Therapy Shows Early Promise for Recurrent High-Grade Glioma
A first-in-kind pilot study reports that systemic targeted alpha therapy with actinium-225 labeled PSMA was feasible, well tolerated, and showed ...
A first-in-kind pilot study reports that systemic targeted alpha therapy with actinium-225 labeled PSMA was feasible, well tolerated, and showed ...
In a groundbreaking study, researchers from Japan, led by Assistant Professor Hiroyuki Suzuki at Chiba University, have introduced a novel ...
The landscape of cancer treatment is constantly evolving, with researchers continuously seeking innovative therapies that can improve patient outcomes. Among ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine